Karl Melber
Free University of Berlin
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Karl Melber.
Antonie Van Leeuwenhoek International Journal of General and Molecular Microbiology | 1992
Gerd Gellissen; Karl Melber; Zbigniew Janowicz; Ulrike Dahlems; Ulrike Weydemann; Michael Piontek; Alexander W.M. Strasser; Cornelis P. Hollenberg
The exploitation of recombinant DNA technology to engineer expression systems for heterologous proteins represented a major task within the field of biotechnology during the last decade. Yeasts attracted the attention of molecular biologists because of properties most favourable for their use as hosts in heterologous protein production. Yeasts follow the general eukaryotic posttranslational modification pattern of expressed polypeptides, exhibit the ability to secrete heterologous proteins and benefit from an established fermentation technology. Aside from the bakers yeastSaccharomyces cerevisiae, an increasing number of alternative non-Saccharomyces yeast species are used as expression systems in basic research and for an industrial application.In the following review a selection from the different yeast systems is described and compared.
Vaccine | 2013
Pascale Buchmann; Claudia J. Dembek; Larissa Kuklick; Clemens Jäger; Raindy Tedjokusumo; Miriam John von Freyend; Uta Drebber; Zbigniew Janowicz; Karl Melber; Ulrike Protzer
Therapeutic vaccines are currently being developed for chronic hepatitis B and C. As an alternative to long-term antiviral treatment or to support only partially effective therapy, they should activate the patients immune system effectively to fight and finally control the virus. A paradigm of therapeutic vaccination is the potent induction of T-cell responses against key viral antigens - besides activation of a humoral immune response. We have evaluated the potential of a novel vaccine formulation comprising particulate hepatitis B surface (HBsAg) and core antigen (HBcAg), and the saponin-based ISCOMATRIX™ adjuvant for its ability to stimulate T and B cell responses in C57BL/6 mice and its ability to break tolerance in syngeneic HBV transgenic (HBVtg) mice. In C57BL/6 mice, the vaccine induced multifunctional HBsAg- and HBcAg-specific CD8+ T cells detected by staining for IFNγ, TNFα and IL-2, as well as high antibody titers against both antigens. Vaccination of HBVtg animals induced potent HBsAg- and HBcAg-specific CD8+ T-cell responses in spleens and HBcAg-specific CD8+ T-cell responses in livers as well as anti-HBs seroconversion two weeks post injection. Vaccination further reduced HBcAg expression in livers of HBVtg mice without causing liver damage. In summary, this study demonstrates therapeutic efficacy of a novel vaccine formulation in a mouse model of immunotolerant, chronic HBV infection.
Biotechnology Advances | 1992
Gerd Gellissen; Zbigniew Janowicz; Ulrike Weydemann; Karl Melber; Alexander W.M. Strasser; Cornelis P. Hollenberg
The methylotrophic yeast Hansenula polymorpha belongs to a limited number of non-Saccharomyces yeast species used as hosts for heterologous gene expression. It has successfully been applied for the production of hormones, antigens and enzymes. The system excells by mitotically stable recombinant strains, high productivity and faithful processing of the produced polypeptides. The favourable characteristics of this microorganism for protein production at an industrial scale are described in the following article focusing on some recent representative examples.
Clinical Chemistry and Laboratory Medicine | 2001
Hans D. Menssen; Karl Melber; Natascha Brandt; Eckhard Thiel
Abstract Undesirable interactions between anticoagulants and diagnostic test kit procedures so far have prevented the development of a single uniform blood sampling tube. Contrary to K2-EDTA, heparin and other anticoagulants, hirudin only minimally alters blood cells and dissolved blood constituents, thus qualifying as a universal anticoagulant for diagnostic purposes. Automated complete blood counts, automated analyses of clinical chemistry analytes and immunohaematology were performed from hirudinised and routinely processed blood obtained from healthy volunteers (n=35) and hospitalised patients (n=45). Hirudin (400 ATU/ml blood) sufficiently anticoagulated blood for diagnostic purposes. The measurements of automated complete blood counts obtained from K2-EDTA-anticoagulated and hirudinised blood correlated significantly as did the measurements of 24 clinical chemistry analytes from hirudinised plasma and serum. Regression analysis revealed that the results of complete blood counts and clinical chemistry tests were predictable from the respective measurements from hirudinised blood (p=0.001). Immunohaematological tests and crossmatching from hirudinised and native blood of the same donors gave identical results. Single clotting factors, but not global coagulation analytes, could be measured from hirudinised blood. Therefore, a universal hirudin-containing blood sampling tube could be designed for automated analysis of haematological, serological and clinical chemistry analytes.
Yeast | 1991
Zbigniew Janowicz; Karl Melber; Armin Merckelbach; Eric Jacobs; Nigel Harford; Martin Comberbach; Cornelis P. Hollenberg
Seminars in Thrombosis and Hemostasis | 2001
Hans D. Menssen; Natascha Brandt; Rainer Leben; Frank Müller; Eckhard Thiel; Karl Melber
Archive | 1997
Karl Melber; Hans D. Menssen; Alexander W.M. Strasser; Eckard Thiel
Archive | 1996
Alexander W M Dr Straser; Karl Melber; Hans Dietrich Dr Mensen; Eckard Thiel
Archive | 1996
Alexander W M Dr Straser; Karl Melber; Hans Dietrich Dr Mensen; Eckard Thiel
Archive | 1996
Alexander W M Dr Straser; Karl Melber; Hans Dietrich Dr Mensen; Eckard Thiel